Clinical endpoints for drug development in prostate cancer

Current Opinion in Urology

Volumn 18, Issue 3, 2008, Pages 303-308

  Ramiah, Veshana ^a,b,c   George, Daniel J ^a,b,c   Armstrong, Andrew J ^a,b,c  

^a DUKE UNIVERSITY   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Castration resistant prostate cancer; Chemotherapy; Hormone refractory metastatic prostate cancer; Novel therapies; Prostate specific antigen; Surrogate endpoints

Indexed keywords

ABIRATERONE ACETATE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CALCITRIOL; CELECOXIB; CETUXIMAB; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; EVEROLIMUS; GENISTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HORMONE ANTAGONIST; IMATINIB; IMMUNOLOGIC AGENT; MITOXANTRONE; OGX 011; PLACEBO; PLATINUM DERIVATIVE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN DERIVATIVE; RAPAMYCIN; SATRAPLATIN; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DISEASE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE MARKER; HUMAN; METASTASIS; PAIN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HUMANS; MALE; NEOPLASM METASTASIS; PAIN MEASUREMENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 41749103582     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3282fb7807     Document Type: Review

References (33)

1. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98:516-521.
2. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25:3965-3970. This study identified 30% decline in PSA and pain responses as having a moderately high degree of surrogacy for the overall survival benefit seen in this study.
3. Scher HI, Halabi S, Tannock I, et al. The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer. ASCO Meeting Abstracts 2007; 25: 5057.
4. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17:3461-3467.
5. Scher HI, Morris MJ, Kelly WK, et al. Prostate cancer clinical trial end points: 'RECIST'ing a step backwards. Clin Cancer Res 2005; 11:5223-5232.
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
7. Moreno J, DeBono JS, Shaffer D, et al. Multicenter study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC). ASCO Meeting Abstracts 2007; 25: 5016.
8. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23:8253-8261.
9. Collette L, Burzykowski T, Carroll KJ, et al. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and Astra-Zeneca Pharmaceuticals. J Clin Oncol 2005; 23:6139-6148.
10. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520.
11. Pollen JJ, Witztum KF, Ashburn WL. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 1984; 142: 773-776.
12. Rock EP, Scott JA, Kennedy DL, et al. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products. J Natl Cancer Inst Monogr 2007; (37):27-30. A discussion of how patient reported outcomes may be used together with other endpoints to assess clinical benefit and drug efficacy for US Food and Drug Administration approval.
13. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004; 96:879-882.
14. Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007; 13:1488-1492. This paper shows that PFS as currently defined may not be a good surrogate for overall survival, highlighting the need for exploring other measures of response to therapy.
15. Sternberg CN, Petrylak D, Witjes F, et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. ASCO Meeting Abstracts 2007; 25:5019.
16. Biotech G. Anticancer programs/satraplatin clinical trials; 24 September 2006. http://www.gpc-biotech.com/en/anticancer_programs/satraplatin/references/ index.html. [Accessed 13 February 2008]
17. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-791.
18. Hricak H, Choyke PL, Eberhardt SC, et al. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007; 243:28-53.
19. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005; 11: 3210-3216.
20. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234:804-814.
21. Thomas G, Speicher L, Reiter R, et al. Demonstration that temsirolimus preferentially inhibits the mTOR pathway in the tumors of prostate cancer patients with PTEN deficiencies. Paper presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 2005; Philadelphia, Pennsylvania, USA; 2005.
22. Amato RJ. Efficacy and safety study of cetuximab or cetuximab plus docetaxel to treat prostate cancer before prostatectomy. http://clinicaltrials. gov/ct2/show/NCT00448097. [Accessed 18 February 2008]
23. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97:1287-1296.
24. Trump DL, Potter DM, Muindi J, et al. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006; 106:2136-2142.
25. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11:5233-5240.
26. Sirolimus before surgery in treating patients with advanced localized prostate cancer. http://clinicaltrials.gov/ct2/show/NCT00311623. [Accessed 18 February 2008]
27. Lerut E, Roskams T, Goossens E, et al. Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC). ASCO Meeting Abstracts 2005; 23: 3071.
28. Carducci MA, Walczak JR, Heath E, et al. A randomized, placebo-controlled trial of celecoxib in men prior to receiving prostatectomy for clinically localized adenocarcinoma of the prostate: evaluation of drug-specific biomarker modulation. ASCO Meeting Abstracts 2007; 25:5001.
29. Fong L, Kavanagh B, Hou Y, et al. Combination immunotherapy with GM-CSF and CTLA-4 blockade for hormone refractory prostate cancer: balancing the expansion of activated effector and regulatory T cells. ASCO Meeting Abstracts 2007; 25:3001.
30. Genistein in treating patients with localized prostate cancer who are planning to undergo radical prostatectomy. http://clinicaltrials.gov/ct2/show/ NCT0058266. [Accessed 18 February 2008]
31. Phase I: Pre-radical prostatectomy RTVP-1 gene therapy for prostate cancer. http://clinicaltrials.gov/ct2/show/NCT00403221. [Accessed 18 February 2008]
32. Neoadjuvant bevacizumab plus docetaxel in high risk patients with prostate cancer undergoing radical prostatectomy. http://clinicaltrials.gov/ct2/ show/NCT00321646. [Accessed 18 February 2008]
33. Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003; 62 (Suppl 1):55-62.